Classer les publications sur l'année

  • Économie de la santĂ©

    Perioperative time and economic impact of an intracameral combination of mydriatics and anaesthetics in routine cataract surgery.

    ZALUSKI S, AMZALLAG T, BOUCHUT P, PINSARD L, THERON JP, TELLOUCK-MORINCOMME J, BAFFERT S.

    Eur J Ophthalmol ; 2023;33(1):239-246

  • Économie de la santĂ©

    Modelling lifetime cost consequences of toric compared with standard IOLs in cataract surgery of astigmatic patients in four European countries

    LAURENDEAU C, LAFUMA A, BERDEAUX G

    J Med Economics ; 12(3):230-237

  • Économie de la santĂ©

    Modelling the lifetime economic consequences of glaucoma in France

    PHILIPPE NORDMANN J, LAFUMA A, BERDEAUX G

    J Med Econ ; 12(1):9-16

  • Économie de la santĂ©

    Modelling lifetimes cost consequences of RESTOR for presbyopia in four European countries

    LAFUMA A, BERDEAUX G

    Eye ; 23(5):1072-80

  • Pharmaco-EpidĂ©miologie

    Les troubles musculosquelettiques en viticulture : prévalence et associations avec le travail de la vigne et les facteurs psychosociaux au travail

    BERNARD C, BOUÉE S, COUROUVE L, ADJEMIAN A, CHRETIEN JC, NIEDHAMMER I

    Arch Mal Prof Environ ; 70:539-549

  • Pharmaco-EpidĂ©miologie

    Incidence of Nd : YAG laser capsulotomies after cataract surgery : comparison of 3 square-edged lenses of different composition

    BOUREAU C, LAFUMA A, JEANBAT V, BERDEAUX G, SMITH ANDREW F

    Can J Ophtalmol ; 44(2):165-170

  • Économie de la santĂ©

    Economics and attitudes regarding spectacles in daily life : a European perspective

    Economics and attitudes regarding spectacles in daily life : a European perspective

    Ophthalmic Epidemiol ; 16(4):218-223

  • Économie de la santĂ©

    Cost of cataract surgery after implantation of three intraocular lenses

    BOUREAU C, LAFUMA A, JEANBAT V, SMITH AF, BERDEAUX G

    Clin Ophtalmol ; 3:277-285

  • Économie de la santĂ©

    Cost effectiveness of Travoprost versus a Fixed Combination of Latanoprost/Timolol in Patients with Ocular Hypertension or Glaucoma : Analysis Based on the UK General Practitioner Research DataBase

    DE NATALE R, LAFUMA A, BERDEAUX G

    Clin Drug Investig ; 29(2):111-120

  • Économie de la santĂ©

    Modelling lifetimes cost consequences of RESTOR in cataract surgery in four European countries

    LAFUMA A, BERDEAUX G

    BMC Ophtalmol ; 8(1):12

  • Pharmaco-EpidĂ©miologie

    Intraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations : a retrospective, multicentre, cross-sectional study

    DENIS P, LAFUMA A, JEANBAT V, LAURENDEAU C, BERDEAUX G

    Clin Drug Investig ; 28(12):767-776

  • Pharmaco-EpidĂ©miologie

    Intermediate visual acuity without spectacles following bilateral ReSTORÂź implantation

    CUQ C, SPERA C, LAURENDEAU C, LAFUMA A, BERDEAUX G

    Eur J Ophtalmol ; 18(5):733-738

  • Économie de la santĂ©

    Costs and persistence of carbonic anhydrase inhibitor versus alpha2 agonists, associated with beta-blockers, in glaucoma an ocular hypertension : an analysis of the UKGPRD database

    LAFUMA A, BERDEAUX G

    Curr Med Res Opin ; 24(5):1519-1527

  • Économie de la santĂ©

    Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care : an analysis conducted on the UK General Practitioner Research Database

    LAFUMA A, LAURENDEAU C, BERDEAUX G

    J Med Econ ; 11(3):485-497

  • Économie de la santĂ©

    Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by the United Kingdom General Practitioner Research Database

    DENIS P, LAFUMA A, BERDEAUX G

    Clin Ophtalmol ; 2(2):321-329